Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.
Increasing use of programmed cell death protein 1/programmed cell death protein 1 ligand inhibition for the treatment of patients with various malignancies such as advanced lung cancer, kidney cancer, and melanoma has resulted in valuable clinical responses, along with the occurrence of new and often puzzling side effects. Known cutaneous effects of CTLA4 and programmed cell death protein 1/programmed cell death protein 1 ligand inhibitors include generalized pruritus, vitiligo, maculopapular lesions, and lichenoid skin eruptions. Alopecia has been the only hair effect previously associated with this class of agents. We describe herein the first case of a persistent curly hair phenotype with the use of nivolumab in a patient with metastatic squamous cell lung cancer.
1 Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, CA, USA.|2 Moores Cancer Center, University of California in San Diego, La Jolla, CA, USA.
Constantin A
CA
Dasanu
2 Moores Cancer Center, University of California in San Diego, La Jolla, CA, USA.
Scott M
SM
Lippman
1 Lucy Curci Cancer Center, Eisenhower Medical Center, Rancho Mirage, CA, USA.|2 Moores Cancer Center, University of California in San Diego, La Jolla, CA, USA.
Steven C
SC
Plaxe
D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D060890:B7-H1 Antigen / Q000037:antagonists & inhibitors; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy*; D006197:Hair / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D000077594:Nivolumab
PD-1/PD-L1 inhibitor; curly hair; lung cancer; nivolumab